Industry News
Maybe not a 'pox on you'
A breakthrough in identifying the mechanisms that control mousepox could pave the way to better protection against the use of smallpox by terrorists.
[ + ]Leukemia expert joins Chemgenex
ChemGenex Pharmaceuticals (ASX: CXS) announced today that leukemia expert Hagop Kantarjian, chairman of the leukemia department at the MD Anderson Cancer Center in Texas, has joined its scientific advisory board. [ + ]
Wily scientific tricks trap foxes
Dr David Dall, CEO of pest-control company Pestat, took a small, anonymous silver spraycan to last month's BioFestival agbiotech conference in Melbourne. [ + ]
Neuroblastoma may be due to gene interference
Researchers at Sydney's Children's Cancer Institute of Australia (CCIA) have identified a possible mechanism for the formation of tumours from embryonic cells. [ + ]
Plant genomics centre lands international research headquarters
The Australian Centre for Plant Functional Genomics, which was officially opened in Adelaide last week, has taken on the headquarters for the International Triticeae Mapping Initiative (ITMI) -- an international forum for the discussion and coordination of public sector research into the genetics and genomics of cereals including wheat, barley, rye and their wild relatives. [ + ]
Peplin granted US patent for its anti-cancer therapeutics
The United States Patent and Trademark Office has granted Peplin Biotech (ASX: PEP) a patent protecting the broad anti-cancer activity of its angeloyl-substituted ingenanes - a class of molecules which includes its lead molecule PEP005. [ + ]
Amrad CEO asks for fair deal on options price
In an unusual move, Amrad (ASX: AML) CEO Pete Smith has asked for options that are due to be granted him after approval at next month's AGM to be granted at the same exercise price as those granted to other employees of the company. [ + ]
Vet Biotechnology targets equine disease
Animal health and stem-cell company Vet Biotechnology has advanced to the starting gate - and is readying to list on the Newcastle Stock Exchange in late October. [ + ]
New biotechs head for the NSX
Having waved goodbye to its first biotech alumnus Living Cell Technologies (ASX:LCT) earlier this year, the Newcastle Stock Exchange is expecting a number of fresh biotech companies to list on the exchange this year. [ + ]
Rockeby lines up diagnostics for FDA approval
Rockeby biomed (ASX: RBY) has lodged a 501(k) submission for regulatory approval of its systemic candidiasis diagnostic SysCan3 with the United States Food and Drug Administration. [ + ]
Capital markets still healthy, say analysts
Analysts say that the IPO market for biotech companies in Australia is healthy right now, and they don't foresee any problems in the near future. [ + ]
Bionomics sets up US subsidiary
Bionomics (ASX: BNO) has set up a US subsidiary to hold intellectual property coming out of its US collaborations. [ + ]
Early success for Biosignal's anti-bacterial contact lenses
Biosignal (ASX:BOS) and the Institute for Eye Research Ltd (IER) have reported interim results from recent in vitro trials of contact lenses with permanently attached furanones. [ + ]
Alchemia gets results with anti-cancer compound
Alchemia (ASX: ACL) will commence the preclinical studies necessary to take its lead anti-cancer compound into human clinical trials after positive results from studies in an animal model of lung cancer. [ + ]
GTG shares soar on back of Applera lawsuit news
The share price of Genetic Technologies (ASX: GTG) has risen over 50 per cent since the judge in GTG's lawsuit against Applera ruled largely in the company's favour during the Markman hearing last Thursday. [ + ]
